Skip to content

Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension

Effects of Paced Breathing Versus Diaphragmatic Breathing Combined With Mat Pilates on Cardiopulmonary Endurance, Dyspnea, Stress, Anxiety, and Quality of Life in Patients With Stage II Hypertension: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07433790
Enrollment
63
Registered
2026-02-25
Start date
2025-09-15
Completion date
2025-11-18
Last updated
2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Stage II Hypertension, Essential Hypertension

Keywords

Mat Pilates, Paced Breathing, Diaphragmatic Breathing, Breathing Exercises, Cardiopulmonary Endurance, 6-Minute Walk Test

Brief summary

This randomized controlled trial aims to compare the effects of mat Pilates combined with paced breathing versus mat Pilates combined with diaphragmatic breathing on stress, anxiety, cardiopulmonary endurance, dyspnea, and quality of life in patients with Stage II hypertension. Participants will be recruited from the Physiotherapy Department of the University of Lahore Teaching Hospital. Outcome measures will include DASS-21, 6-Minute Walk Test (6MWT), Modified Borg Dyspnea Scale, and SF-12 Health Survey. The intervention will be conducted three times per week for six weeks.

Detailed description

This study is a randomized controlled trial conducted at the Physiotherapy Department of the University of Lahore Teaching Hospital, Lahore. A total of 63 hypertensive patients will be screened from the Outpatient Department (OPD) after clinical diagnosis by a qualified medical specialist. Eligible participants who meet inclusion criteria and provide written informed consent will be enrolled using a non-probability purposive sampling technique. Participants will be randomly allocated into two parallel groups using a sealed envelope method to ensure allocation concealment. Participants in: Group A: Will receive mat Pilates exercises combined with paced breathing training. Group B: Will receive mat Pilates exercises combined with diaphragmatic breathing training. Both groups will undergo supervised intervention sessions three times per week on alternate days for a total duration of six weeks. Each session will last approximately 45-60 minutes. Outcome measures will be assessed at baseline and at the end of the six-week intervention period.

Interventions

Standardized mat-based Pilates exercises focusing on breathing control, core stability, postural alignment, flexibility, and strengthening. Sessions will be supervised and conducted three times per week on alternate days for six weeks, with each session lasting approximately 45-60 minutes.

BEHAVIORALPaced Breathing

Participants will perform paced breathing exercises using a controlled respiratory rate guided by therapist instruction during sessions. Paced breathing will be integrated with mat Pilates sessions, three times per week for six weeks.

Sponsors

University of Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Participants and care providers will not be blinded due to the nature of the interventions.

Intervention model description

Participants will be randomly assigned into two parallel groups to receive either mat Pilates combined with paced breathing or mat Pilates combined with diaphragmatic breathing for six weeks.

Eligibility

Sex/Gender
ALL
Age
40 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 40 to 50 years * Clinically diagnosed Stage II hypertension confirmed by a qualified healthcare provider * On a stable antihypertensive medication regimen for at least 4 weeks * Moderate dyspnea levels as measured by the Modified Borg Dyspnea Scale * Not currently participating in any structured exercise or rehabilitation program * Able to understand instructions and complete questionnaires * Willing to provide written informed consent

Exclusion criteria

* Uncontrolled hypertension (e.g., blood pressure greater than 180/110 mmHg) * History of recent cardiovascular events (e.g., myocardial infarction within the past 6 months) * Severe neurological or musculoskeletal disorders limiting mobility * Severe anxiety or stress requiring psychiatric intervention * Severe cognitive impairment or communication barriers * Currently enrolled in another clinical trial or structured wellness program * Any medical contraindication to physical activity as advised by a physician

Design outcomes

Primary

MeasureTime frameDescription
Stress and Anxiety Levels (DASS-21)Baseline and at 6 weeksStress and anxiety levels will be assessed using the Depression Anxiety Stress Scale - 21 items (DASS-21). Each subscale consists of 7 items scored on a 4-point Likert scale (0 = Did not apply to me at all to 3 = Applied to me very much or most of the time). Scores are multiplied by 2 to calculate final subscale scores. Higher scores indicate greater psychological distress.

Secondary

MeasureTime frameDescription
Cardiopulmonary Endurance (6-Minute Walk Test)Baseline and at 6 weeksCardiopulmonary endurance will be measured using the 6-Minute Walk Test (6MWT). The total distance walked in meters over six minutes will be recorded. Higher distance indicates improved cardiopulmonary endurance.
Dyspnea Severity (Modified Borg Dyspnea Scale)Baseline and at 6 weeksDyspnea will be assessed using the Modified Borg Dyspnea Scale, a numerical rating scale ranging from 0 (no breathlessness) to 10 (maximal breathlessness). Higher scores indicate more severe dyspnea.
Health-Related Quality of Life (SF-12)Baseline and at 6 weeksQuality of life will be assessed using the 12-Item Short Form Health Survey (SF-12), which evaluates physical and mental health domains. Higher scores indicate better perceived health status.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026